ELIGARD 7.5MG INJECTION contains Leuprolide which belongs to the group of medicines called Gonadotropin Releasing Hormone (GnRH) agonist. It is used for palliative management (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer. It is also used in children to manage central precocious puberty (CPP). Advanced prostatic cancer is the cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness. Central precocious puberty (CPP) is the early onset of sexual characteristics in girls (generally earlier than 8 years) and boys (generally earlier than 9 years of age in boys) due to activation of pubertal pituitary gonadotropins. It may result in diminished adult height. Do not receive ELIGARD 7.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs. Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes. Before receiving this medicine, inform your doctor if you have history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. ELIGARD 7.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children (below 2 years). It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving. The common side effects associated with the use of ELIGARD 7.5MG INJECTION are hot flashes/sweating, general pain, headache, infection, gastrointestinal disorders, swelling due to water retention, and respiratory disorders. Consult your doctor if any of these side effects worsens.
No content available
